Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Clinical Trial of EG-501 for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

NCT07281105 is registered in ClinicalTrials.gov with Evergreen Therapeutics, Inc. as lead sponsor.

NCT NCT07281105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07281105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Clinical Trial of EG-501 for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
Lead sponsor
Evergreen Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 23, 2018
Completion date
August 12, 2025
Enrollment
131 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, neuropsychiatric systemic lupus erythematosus, systemic lupus erythematosus (sle)